[
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg1L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 1,
    "text": "Common Skin D\n\nSurangkana Veeranawin, MD\n\nMSc, Queen Mary University of\n\nMmed, University of Sydney\n\nDipDerm RCPS(Glas.)\n\nDiplomate American Broad of",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg2L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 2,
    "text": "Acne Vulgaris\n\nInflammatory disorder of p\n prevalence in adolescenc\n\nHistory: often asymptomat\n although can be tender (n\n\nPhysical: two types of lesio\n neck, chest and back\n\n - Noninflammatory; open(“\nhead”) comedones\n\n - Inflammatory; papules, pu\n(leave scars)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg2R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 2,
    "text": "pilosebaceous follicle with a 90%\nce and young adulthood.\n\n tic lesions (especially comedone),\n nodules)\n\nons, predominantly affect face,\n\n“black head”) and closed (“white\n\n ustule, cysts, nodule: deep lesions",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg3L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 3,
    "text": "Acne Vulgaris\n\n 4 Major components\n\n • Abnormal follicular kerati\n desquamate to the surfa\n • Sebum over production s\n • Propionibacterium acnes\n sebum-cell mixture.\n Inflammation\n\n Other components; gene\n agents, medication (stero\n antiepileptics, oral contra\n Congenital Adrenal Hype",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg3R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 3,
    "text": "nization: follicular wall cells fail to\n ce in the normal manner.\nsecondary to androgen\ns infection; they grow in the\n\netic factors, occlusive cosmetic\noids, ACTH, androgens, lithium,\naceptives), diseases (PCOS,\nerplasia)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg4L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 4,
    "text": "Acne\n\nTreatment Strategies\n\n - Retinoid for clearing pores an\nconditions\n\n - Small inflammatory lesions \n Topical Antibiotic\n\n - Large inflammatory lesions",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg4R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 4,
    "text": "nd comedones for all acne\n\nTopical Benzoyl Peroxide (BP) &\n\n Oral antibiotic",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg5L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 5,
    "text": "Acne\n\nMild Topical Only\n Decrease follicular pluggi\n • Retinoid\n • Nightly\n • Adapalene (Differin\n • Salycilic acid wash/scr\n\n Decrease P. Acne\n • Topical Antibiotic\n • Clindamycin\n • Benzoyl peroxide; bac",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg5R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 5,
    "text": "ing\n\n ); if can not tolerate retinoid\nrub\n\n terialcidal, decrease sebum/oil",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg6L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 6,
    "text": "Acne\n\nModerate or nonresponsive to\n\n Add oral antibiotic\n • Tetracycline\n 250 – 500 mg twice/da\n • Minocycline\n 50 – 100 mg twice/day\n • Doxycycline\n 50 – 100 mg twice/day\n\n Add chemical peel Sa",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg7L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 7,
    "text": "Acne\n\nOther treatment\n\n - comedone extraction, int\npapulonodules, cysts), oral c\nandrogenic such as cyprote\ntherapy, spironolactone (re\n– 200 mg/day), dermabrasio\n\n - Patients should be forewa\nthe first month of systemic th\ncomes to the surface. Also,\nwk before benefits are note",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg7R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 7,
    "text": "tralesional cortisone injection (for\n contraceptives (esp. antierone acetate), photodynamic\n duces androgen production; 50\n on\n\narned of acne exacerbations in\n herapy as deep-seated acne\n systemic therapy can required 6\ned",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg8L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 8,
    "text": "Rosacea\n\nChronic vascular & acneiform d\n\nCommon chronic inflammatory\n and vasculature of the face\n\nRole of Demodex mite controve\n\nIncrease reactivity of capillaries\n leading to telangiectasia",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg8R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 8,
    "text": "disorder\n\ny disorder of pilosebaceous units\n\nersial\n\ns Flushingultimately",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg9L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 9,
    "text": "Rosacea\n\nEasy and recurrent flushin\n\nSensitive skin\n\nMore common in fair skin\n\nMay complain of dry and\n\nFemale > male\n\nPeak incidence 30-50 yr",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg10L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 10,
    "text": "Rosacea\n\nEXACEBATE BY\n\nHeat,rapid change in tem\n\nSun exposure\n\nCold\n\nEtOh\n\nStress\n\nSpicy food\n\nHot food/beverage\n\nCaffeine",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg11L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 11,
    "text": "Clinical appearance: Ery\n and pustules of central fa\n to acne.\n\nErythema of the nose is h\n\nAccompany with, sebac\n dermatits & facial lymphe",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg11R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 11,
    "text": "ythema, telangiectases, papules,\n ace; no comedones in contrast\n\nhighly characteristic of rosacea\n\nceous hyperplasia, seborrheic\n edema more common",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg12L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 12,
    "text": "Rosacea\n\nPredominantly central fa\n\n - Forehead\n\n - Cheeks\n\n - Nose\n\n - Chin\n\n - Occasionally eyelids",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg13L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 13,
    "text": "Rosacea\n\n4 Major subtypes\n Vascular rosacea ( Erythema\n Papulopustular rosacea\n Ocular rosacea: gritty, conju\n photophobia. (The eye is invo\n Nasal sebaceous hyperplasi\n inflammation may progress t\n male)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg13R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 13,
    "text": "atotelangiectatic rosacea)\n\nunctival injection, styes and\n olved in about 50% of cases)\n a (rhinophyma): chronic\n o rhinophyma (more common in",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg16L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 16,
    "text": "Rosacea\n\nInvestigation\n\n - Clinical diagnosis\n\n - Skin biopsy to rule out lu\n\nDifferential Diagnosis\n\n - Acne - Lupus eryt\n\n - Seborrheic dermatitis -",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg16R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 16,
    "text": "pus or sacoidosis\n\nthematosus - Sarcoidosis\n\n- Perioral dermatitis",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg17L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 17,
    "text": "Rosacea\n\n Management\n - Based on severity and subty\n - Lifestyle modification : Avoid\navoidance.\n - Topical antibiotic\n Metronidazole 0.75% ge\n Sodium sulfacetamide lo\n Azelaic acid QD",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg17R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 17,
    "text": "ype.\nd triggers ; sun protection &\n\n l or 1% cream bid\n otion 10% bid",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg18L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 18,
    "text": "Rosacea\n\n - Oral antibiotic (moder\n inflammatory papulop\n\n Tetracycline 500 mg\n Minocycline 100 mg\n Doxycyline 20 mg p\n therapy) or 100 mg\n\n - Isotretinoin and pred",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg18R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 18,
    "text": "rate to severe cases with\npaustular component)\n\ng po BID\ng OD – BID\npo bid (subantimicrobial dose\n po qd-bid\n\n nisolone for very severe cases",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg19L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 19,
    "text": "Rosacea\n\n- Light therapy\n Treatment of Choice \n (595 nm) for telangiect\n Ablative laser (CO2) fo\n\n- Ophthalmologist to assess f\n(blepharitis, conjunctivitis)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg19R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 19,
    "text": "IPL (400nm – 1200nm), PDL\n tases\n or rhinophyma\n\n for ocular involvement",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg20L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 20,
    "text": "Pityriasis rosea\n\nAcute, self-limited papulo\n exanthem in 15-40 yr.\n\nThe primary lesion is an o\n plaque that forms a roun\n center.\n\nIt evolves rapidly, usually\n heralds the eruption, the\n\nClinical appearance: Sca\n predominantly trunk affe",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg20R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 20,
    "text": "osquamous inflammatory skin\n\n val, salmon-colored, 1-10 cm\nnd collarette of scale in the\n\n beginning with patch that\n so-called “herald patch.\n\n aly pink-erythematous plaques;\nected, in “Christmas-tree” pattern",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg21L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 21,
    "text": "Pityriasis rosea\n\nEtiology: Possibly triggered\n\nHistory: May be pruritic or a\n mild constitutional sympto\n\nLesions are found on the tr\n and extremities\n\nThe number of lesions is hig\n to the neck and proximal\n\nNumerous lesions may app\n the groin and lower abdo\n especially in children",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg21R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 21,
    "text": "d by human herpes virus 7\n\n asymptomatic; preceding URTI or\noms\n\n runk and usually spare the face\n\n ghly variable. Plaques may extend\n limbs\n\n pear. A concentration of lesions on\n men is highly characteristic,",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg23L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 23,
    "text": "Pityriasis rosea\n\nCourse: Self-resolving in 6\n\nInvestigations: Clinical; sc\n order RPR (R/O syphilis), o\n\nDDx: Eczema, psoriasis, ti\n dermatitis",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg23R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 23,
    "text": "6-8 weeks\n\ncraping for KOH (R/O tinea) or\nor skin biopsy if uncertain.\n\n nea corporis, syphilis, seborrheic",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg24L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 24,
    "text": "Pityriasis rosea\n\nManagement\n\n - Reassurance is key\n\n - Symptomatic managem\nsteroids, antihistamines); me\nitching\n\n - Erythromycin 250 mg, q.i\ndoses in children for 2 week\n\n - Light therapy (e.g. UVB)\nrelieve pruritus",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg24R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 24,
    "text": "ment of pruritus (e.g. mild topical\nentholated lotion or sprays for\n\n .d or 25-40 mg/kg in four divided\nks may clear the eruption\n\n may help hasten resolution and",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg25L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 25,
    "text": "Lichen Planus\n\nAcute or chronic inflamm\n scalp hair follicles, mucou\n 10%)\n\nEtiology: Likely an immun\n oral erosive lichen planus\n (Characteristic eruption o\n\nHistory: Uncommon in ch\n Pruritus common; oral les\n symptomatic. Ask about\n transfusions) for oral erosi",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg25R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 25,
    "text": "matory disorder affecting the skin,\n us membranes, and nails (5%-\n\nnologically mediated reaction;\n s associated with hepatitis C\n of unknown etiology)\n\nhildren. Family history is 10%.\nsions may or may not be\n Hep C risk factors (e.g.,\n ive LP. May be drug-induced.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg26L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 26,
    "text": "Lichen Planus\n\nPhysical: 7 P’s\n\n - Planar (flat-topped) - Pruri\n\n - Purple - Poly\n\n - Papules - Peni\n\n - Prolonged course (up to 18 mo\n\nDistributed on flexor surfaces,\n patches or erosions – Wickha\n\nKoebner phenomenon: appe",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg26R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 26,
    "text": "itic (intense)\n\nygonal\n\n ile (commonly affected)\n\n o; longer in some case)\n\n , penis (glans), mouth (lacy white\nm striae)\n\nearance of lesions at sites of trauma",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg28L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 28,
    "text": "Lichen Planus\n\nCourse: May resolve spon\n course (esp. oral LP); incr\n\nDDx: Drug reaction, Pityri\n\nInvestigations: Skin biopsy",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg28R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 28,
    "text": "ntaneously or have chronic\nrease risk of oral SCC in oral LP\n\n asis rosea, Psoriasis\n\ny if unsure of diagnosis",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg29L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 29,
    "text": "Lichen Planus\n\n Management\n\n Topical: Mild to high potency steroid\n hypertrophic/thick. Triamcinolone a\n\n Systemic: (if severe and generalized\n\n- Prednisolone; a 4 weeks course star\n\n- Retinoids\n\n- UV therapy\n\n- Cyclosporine\n\n- Metronidazole 500 mg po bid * 6 wk",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg29R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 29,
    "text": "d bid for 2 weeks; intralesional if\nacetonide in adhesive base for oral lesion\n\nd)\n\n rting at 1 mg/kg q.d.\n\n k, sedative antihistamines for itching",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg30L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 30,
    "text": "Psoriasis\n\nCommon (1%-2% prevale\n inflammatory skin disease\n\nOnset: any age, peaks la\n\nEtiology: Genetic & envir\n epidermal differentiation\n and maintained primarily\n\nHistory: Visible itchy red p\n and peeling. May have j\n preceding URTI (Streptoc\n smoking, alcohol & stress",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg30R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 30,
    "text": "ence), chronic, recurrent\ne with unpredictable course.\n\nate twenties\n\nronment factors; abnormal\nn and hyperproliferation initiated\ny by T-cell\n\nplaques with increase skin scaling\n oint pain (7-20%). May have\ncoccus infection). Worsened by\n , physical trauma",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg31L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 31,
    "text": "Psoriasis\n\nPhysical: Most common c\n Characteristic sharply de\n with silvery-white scale; d\n (elbows, knees), scalp, sa\n\n- Nail psoriasis: Pitting, thick\n plate off of distal nail bed\n\n- Koebnerization = new les\n (as with lichen planus)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg31R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 31,
    "text": "chronic plaque psoriasis.\nefined, erythematous plaques\ndistributed over extensor surfaces\nacrum and other sites\n\n kening, “oil-drop”, lifting of nail\nd (onycholysis)\n\nsions occur at sites of skin trauma",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg32L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 32,
    "text": "Psoriasis\n\nVariants: Vulgaris, palmo\n streptococcal pharyngiti\n inverse (affects folds and\n\nDrug may precipitate or\n Antimalarials, clonidine, i\n NSAIDS, quinidine, some\n withdrawal and terfenad",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg32R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 32,
    "text": "plantar, guttate (may follow\n s), erythrodermic, pustular,\nd flexor surfaces)\n\n exacerbate psoriasis:\n ndomethacin, iodine, lithium,\n beta-blockers, steoids\ndine.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg38L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 38,
    "text": "Psoriasis\n\nIn 10-20% may be associa\n commonly of the small jo\n requires systemic Tx\n\nInvestigation: Clinical dia\n\nDDx: Drug reaction, ecze\n rubra pilaris",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg38R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 38,
    "text": "ated with psoriatic arthritis, most\noints of the hands and feet;\n\nagnosis; skin biopsy if uncertain\n\nema. Lichen planus, pityriasis",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg39L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 39,
    "text": "Psoriasis\n\nTopical\n\n- Steroids; Fast, temporary re\n\n- Calcipotriol ointment, 100\n tolerated + topical steroi\n\n- Tazarotene 0.05%, 0.1% c\n\n- Tar preparations; low cos\n irritation, clothing stains)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg39R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 39,
    "text": "elief (atrophy, telangiectasia)\n\n 0g bid. on weekdays as\n d bid., weekends\n\ncream qhs\n\n st, effective (limited by odor,",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg40L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 40,
    "text": "Psoriasis\n\nSystemic\n\n- Methotrexate; Folic acid a\n synthesis & causes immuno\n hepatic toxicity, nausea, a\n\n- Cyclosporine; Immunosup\n production & thus reduces\n hypertension)\n\n- Acitretin; Inhibits cell replic\n differentiation within the e\n or UVB.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg40R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 40,
    "text": "antagonist that inhibits DNA\n osuppression (Bone marrow and\nanorexia, fatique, oral ulceration)\n\n pressant that inhibits IL-2\n s T-cell proliferation (Renal toxicity,\n\ncation by modulating cellular\nepidermis. May combine with PUVA",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg41L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 41,
    "text": "Psoriasis\n\nPhototherapy\n\n- UVB (narrowband ultravio\n week.\n\n or\n\n- PUVA; Interferes (Psoralen\nsynthesis, decreases cellular\napoptosis of cutaneous lym\nimmunosuppression. Admin\nthen tapered. (Skin cancer",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg41R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 41,
    "text": "olet B); administer 2-5 times per\n\n plus ultravioletA) with DNA\n r proliferation, and induces\nmphocytes leading to localized\n ister 3 times per week until clear,\n development, photoaging)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg42L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 42,
    "text": "Psoriasis\n\nNewer Biological Agents\n\n- Alefacept ; Fusion protein of Fc recep\n when effective long remissions; monit\n\n- Efalizumab ; Humanized monoclonal\n ICAM interaction. (SC; rapidly effecti\n thrombocytopenia)\n\n- Etanercept ; Fusion protein directed a\n psoriasis & psoriatic arthritis; rapid ons\n\n- Infliximab ; Chimeric monoclonal ant\n very effective; must do PPD; infusion\n\n- Adalimumab ; Fully humanized anti-T\n of the biologics, still being studied.\n\nNote TNF drugs avoid or use with caution\ndisorders. Increased risk of opportunistic",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg42R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 42,
    "text": "ptor of human lgG1 and LFA3. (IM;\n toring of CD4 q wk; slow onset)\n\n antibody to CD11 a; blocks LFA-1/\n ve, but rebound; risk of\n\n against soluble TNFa(SC; effective for\n set; no monitoring; use +/- MTX)\n\ntibody against TNFa (IV; Fast onset and\n reactions.\n\nTNF monoclonal antibody (SC; newest\n\nn in presence of CHF, demyelination\n infections.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg43L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 43,
    "text": "Psoriasis\n\nScalp; 10% salicylic acid\n qd, steroid lotion, calcipo\n\nNails; Intradermal triamci\n (painful), methotrexate, n\n\nGeneralized psoriasis (>1\n therapy, best administere",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg43R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 43,
    "text": "in mineral oil qhs, tar shampoo\notriol lotion.\n\ninolone acetonide injections\nnew biologics.\n\n0% BSA) benefits from systemic\ned by an experienced physician",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg44L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 44,
    "text": "Vitiligo\n\nAcquired skin disorder ch\n areas of complete epide\n pathogenesis theories; lik\n component\n\nHistory; Asymptomatic: 50\n affected, rare in infancy\n\nAssociated with immune\n thyroid disease, diabetes\n autoimmune diseases oc",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg44R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 44,
    "text": "haracterized by well-defined\nermal depigmentation; various\nkely a large autoimmune\n\n 0% present before age 20, 1-2%\n & old age\n\n disorder; therefore workup for\n s, pernicious anemia and other\nccasionally indicated",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg45L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 45,
    "text": "Vitiligo\n\nPhysical: Stark white patc\n hair in vitiligo patches ap\n\nIncreased risk of sunburn\n areas\n\nInvestigations; Wood’s la\n & helps determine exten\n glucose\n\nDDx; Leprosy, pityriasis alb\n sclerosis, nevus depigme",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg45R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 45,
    "text": "ch with well-demarcated border;\nppears white or gray\n\n and skin cancer in amelanotic\n\n mp accentuates areas of vitiligo\n t; consider TSH and fasting blood\n\n ba, tinea vesicolor, tuberous\n ntosus",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg47L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 47,
    "text": "Vitiligo\n\n Management\n\n- Mainly for cosmetic, psychological\n\n- Topical steroids and new topical im\n PUVA, NB-UVB, phototherapy\n\n- Camouflage makeup\n\n- Note that facial and more proximal\n\n- Surgical transplants can be conside\n\n- If extensive, can consider bleaching\n color\n\n- -Advise; importance of sun protecti",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg47R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 47,
    "text": "burden\n\nmmunomodulators (tacrolimus & pimecrolimus),\n\n l lesions respond better than acral lesions\n\n ered in stable vitiligo\n\n g of nonaffected areas to result in total white\n\n on",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg48L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 48,
    "text": "Molluscum Con\n\nEtiology: Self-limited viral\n poxvirus affecting mainly\n\nImmunocompromised pa\n more widespread and la\n\nHistory: Asymptomatic; o\n very common in children\n autoinoculation. Lesions\n spread rapidly in patients",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg48R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 48,
    "text": "ntagiosum\n\n infection of skin caused by\n y children.\n\n atients (e.g., HIV) may develop\n arger lesions\n\n ccasional perilesional pruritus,\n n. Spread by direct contact or\n tend to be more numerous and\n s with atopic dermatits.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg49L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 49,
    "text": "Molluscum Con\n\nPhysical: 2- to 6- mm firm, f\n umbilicated pearly papule\n trunk and face of children\n active adults\n\nMolluscum papules in a ch\n Lesions can be spread by\n will be resolve with develo\n\nCourse: lesions typically inv\n mo; may develop adjace\n\nInvestigation: clinical diag\n\nDDx: BCC, milia, other infe",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg49R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 49,
    "text": "ntagiosum\n\n flesh colored, dome-shaped,\n es; most common affected sites –\n n, genital/inner thigh of sexually\n\n hild in the periorbital region.\n picking and scratching. Lesions\n opment of cellular immunity.\n\n volute spontaneously within 9-12\n nt eczema (10%)\n\n nosis, biopsy if uncertain\n\n ection, warts",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg50L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 50,
    "text": "Molluscum Con\n\n Management\n\n- Observation\n\n- Liquid Nitrogen Cryotherapy\n\n- Curettage: may be uncomfortable\n\n- Papule incision with a scalpel blade\n contents\n\n- Topical cantharidin 0.7%: Blistering w\n\n- Imiquimod cream, Tretinoin cream\n\n- In children with widespread involve\n mg/kg/d ) for 2 mo.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg50R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 50,
    "text": "ntagiosum\n\n es or at home sharp fingernail and expression of\n\n will occur\n\n ment, may consider oral cimetidine (40",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg52L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 52,
    "text": "Pityriasis Versicolo\n\nEtiology : Common superfi\n caused by Malassezia furfu\n organism is part of normal\n\nHistory : May itch but usua\n typically affected (years o\n commonly recurs (40-60%)\n environments.\n\nCushing disease, pregnan\n therapy, immunosuppressi\n resistance, allowing this no\n yeast to poliferate",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg52R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 52,
    "text": "or (Tinea Versicolor)\n\n icial cutaneous fungal infection\n ur (Pityrosporum orbiculare), The\n skin\n\n ally asymptomatic, young adults\n of higher sebaceous activity) ;\n ) ; more common in hot and humid\n\n cy, mulnutrition, corticosteroid\n ion, oral contraceptives may lower\n ormally non-pathogenic resident",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg53L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 53,
    "text": "Pityriasis Versicolo\n\nPhysical : Round to oval m\n trunk extending to the up\n different colors: White, or\n fine scale; postinflammat\n noted rather than initial e\n\nInvestigations: KOH test re\n meatballs” (hyphae & sp\n yellow-brown fluorescenc\n uncertain.\n\nDDx : Tinea corporis, vitilig",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg53R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 53,
    "text": "or (Tinea Versicolor)\n\n macules and patches on the\n pper arms, neck, abdomen;\n range-brown, dark-brown; very\n tory hypopigmentation is often\n erythema.\n\n eveals diagnostic “spaghetti &\npores); Wood’s lamp shows\n ce. Skin biopsy if diagnosis\n\n go, psoriasis.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg56L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 56,
    "text": "Pityriasis Versicolo\n\nManagement\n Topical or systemic treatm\n Nizoral shampoo (ketocon\n trunk skin, lathered for 5 m\n Topical selenium sulfide 2.\n Topical nizoral cream 2% (\n Systemic ketoconazole 20\n 400 mg x 1. Postinflammat\n 6 – 12 mo.\n Even with treatment, tend\n Zinc pyrithione soap lathe\n times weekly for preventio",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg56R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 56,
    "text": "or (Tianea Versicolor)\n\nment.\n nazole 2%) applied onto dampened\nmin before rinsing, x 3 d.\n 5% shampoo applied for 15 min x 3 d.\n (ketoconazole) bid x 2 wk.\n 00 mg po qd x 5 – 7 d or fluconazole\n tory hypopigmentation may persist for\n\n dency to recur in summer.\n r may be applied to the body 1 – 3\n on.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg57L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 57,
    "text": "Tinea (Dermato\n\nDermatophyte digest an\n nails and hair; incubation\n\nTrychophyton, Microspor\n commonly involved.\n\nRisk Factors; Hot, humid e\n maceration of the skin, o\n mellitus, immunosuppress\n\nHistory: Asymptomatic; o",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg57R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 57,
    "text": "ophyte) Infection\n\n d invade keratin then infect skin,\n n period = 1-3 weeks\n\n rum, Epidermophyton species\n\n environment, sweating or\n occlusive footwear, Diabetes\n sion\n\n ccasionally mild pruritus",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg58L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 58,
    "text": "Tinea (Dermato\n\nPhysical; Scalp hair and g\n affected during childhoo\n are more common after\n\nImmunologic response to\n result in a dermatophytid\n acral surfaces, especially",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg58R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 58,
    "text": "ophyte) Infection\n\n general body surfaces mostly\n od; hand, foot or nail infections\n puberty\n\n o a dermatophyte infection may\n d reaction: Vesicular eruption on\n y the palms",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg61L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 61,
    "text": "Tinea (Dermato\n\nInvestigations; Skin scrapi\n Septate hyphae branchi\n fungal culture\n\nDDx; Eczema, granuloma",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg61R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 61,
    "text": "ophyte) Infection\n\n ing analysis with KOH prep –\n ng at various angles are seen;\n\n a annulare, psoriasis",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg62L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 62,
    "text": "Tinea Capitis\n\nCaused by invasion of stratum\n hyphae.\n\nFour clinical infection pattern\n\n- Seborrheic dermatitis type- D\n\n- Black dot pattern- hyphae inv\n scalp surface. Broken shaft lik\n without inflammation\n\n- Inflammation tinea capitis (ke\n pustules, surface exudate\n\n- Pustular- Pustules areas witho\n present, look like scalp bacte",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg62R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 62,
    "text": "m corneum and hair shaft with fungal\n\nns;\n\n iffuse, patchy scale on scalp\n\n vade hair shaft. Hair then broke at\nke black dots. Round area of alopecia\n\n erion)- Deep boggy round masses with\n\n ut scaling, significant hair loss may be\nerial infection.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg66L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 66,
    "text": "Tinea Capitis\n\nManagement\n\n- Examine sibling and househo\n contaminated objects.\n\n- Griseofulvin; usually 6-12 wee\n\n- Itraconazole and fluconazole\n 150 mg once weekly for 4 we\n\n- Shampoo with selenium sulfid\n for the first 2 weeks, then twic\n oral therapy. Shampoo is left\n\n- Consider suppression kerion in\n mg/kg qd or intralesional triam",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg66R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 66,
    "text": "ld members, clean or discard\n\n ks\n\ne; taken for 4-8 weeks. A single dose of\neeks also be effective for older children\n\nde 1% or ketoconazole every other day\nce weekly throughout course of rest of\n for 5 min\n\n nflammation with prednisolone 1-2\n mcinolone 10 mg/cc",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg67L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 67,
    "text": "Erythema Nodo\n\nCommon form of septal panniculitis\n an associated trigger\n\n- Infections; Bacterial (e.g., streptococ\n (tuberculosis)\n\n- Drugs; e.g., oral contraceptives, sulfo\n\n- Sarcoidosis\n\n- Inflammatory bowel disease\n\n- Behcet disease\n\n- Malignancy\n\n- - Pregnency",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg67R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 67,
    "text": "osum\n\n that is usually a reactive skin response to\n\n ccal pharyngitis), microbacterial\n\n onamides",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg68L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 68,
    "text": "Erythema Nodo\n\nHistory; Lesions may be a\n leg edema and arthralgi\n\nPhysical; painful, dull, ery\n diameter, located on an\n woman. No ulceration, d\n\nInvestigation; Through rev\n x-ray and throat swab\n\nDDx; Insect bite reaction",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg68R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 68,
    "text": "osum\n\nassociated with fever, malaise,\n a. Resolution after 2-6 wk\n\n ythematous nodules 1-5 cm in\n terior lower legs of young\n discharge or scarring\n\n view of systems: CBC, UA, chest\n\n , erysipelas, urticaria",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg70L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 70,
    "text": "Erythema Nodo\n\nManagement\n\n- Investigate for and treat\n\n- Most patients benefit from\n compresses, elevating le\n\n- Less common Tx choice;\n dapsone",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg70R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 70,
    "text": "osum\n\n underlying cause.\n\n m bed rest, applying ice or cool\n gs & NSAIDs\n\n Oral prednisolone, colchicine,",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg71L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 71,
    "text": "Necrobiosis lipo\n\nAn inflammatory conditio\n When present, it is often a\n\nLesions usually develop s\n asymptomatic, onset ma\n disease most common st\n 75% of those affected ar",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg71R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 71,
    "text": "odica\n\n on of degenerative collagen.\n associated with diabetes\n\n lowly and are often\n ay occur at any age but the\n tarts at 3rd – 4th decade. About\n e women",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg72L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 72,
    "text": "Necrobiosis lipo\n\nPhysical Findings\n Lesion are usually limited t\n on calve and thighs, and\n scalp.\n They begin as round, viola\n The advancing border is re\n characteristic orange-yell\n and shows a shiny, waxy s\n Ulceration may occur, pa\n cases. These ulcers are ex\n The number or severity of\n correlated with the degre\n The course is unpredictab\n scarring, or can be chroni",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg72R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 72,
    "text": "odica\n\n to the anterior shins but may be seen\n rarely on the arms, hands, feet and\n\n aceous patches and slowly expand.\n ed, and the central area turns a\n ow brown. The central area atrophies\n surface with prominent telangiectasias.\n rticulary after trauma, in about 15% of\n xquisitely tender.\n lesions or ulcerations has not been\n ee of diabetic control.\n le. Lesions usually heal with atrophic\n c and recurrent.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg73L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 73,
    "text": "Necrobiosis lipo\n\nTreatment\n Topical and intralesional s\n promote further atrophy. M\n corticosteroids can be use\n Intralesional injections of t\n canbe helpful.\n A short course (5-6 weeks)\n considered if disease activ\n is rarely the case.\n Pentoxifylline (Trental) 400\n some and has been used\n for ulcerating necrobiosis\n Skin grafting can be perfo",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg73R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 73,
    "text": "odica\n\n teroids slow the inflammation but may\n Middle- to high-potency\n ed under occlusion.\n riamcinolone acetonide 10 mg/mL\n\n ) of oral corticosteroids can be\n vity and symptoms are severse, but this\n\n mg t.i.d. has been advocated by\n in combination with low-dose aspirin\n lipoidica.\n ormed for extensive disease.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg74L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 74,
    "text": "Seborrheic Kera\n\n Common idiopathic benign e\n Common in fourth decade\n Males and females equally a\n More common in fair skin\n Possibly autosomal dominant\n Gradual development; occa",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg74R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 74,
    "text": "atosis - SK\n\n epidermal growth\n\n ffected\n\n t\nasionally pruritic or sore",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg75L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 75,
    "text": "Seborrheic Kera\n\n Well circumscribed epide\n Waxy round-oval papules\n crusted surface. Sharp bor\n “Stuck on” appearance\n Starts as light brown macu\n time\n Also, smooth-surfaced lesio\n horn pearls embedded in\n surface.\n Variably pigmented and s\n Most commonly: trunk, ne",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg75R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 75,
    "text": "atosis - SK\n\nermal growth, raised lesions\n and plaques with verrucous or\n rder\n\n ule larger and verrucous with\n\n ons contain dark or light round\n the lesion or protruding from the\n\n size\n ck, arms, scalp; wide range of size",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg76L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 76,
    "text": "Seborrheic Kera\n\nLeser-Trelat sign: Sudden, e\n elderly individuals, often wi\n a sign of an associated inte\n others) malignancy as part",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg76R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 76,
    "text": "atosis - SK\n\neruptive seborrheic keratoses in\n ith inflammatory base may be\n ernal (stomach cancer &\n t of paraneoplastic syndrome",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg77L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 77,
    "text": "Seborrheic Kera\n\nInvestigation: Clinical dia\n\nDDx: AK, BCC, lentigo, m",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg77R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 77,
    "text": "atosis - SK\n\nagnosis; skin biopsy if uncertain.\n\n elanoma, nevus, skin tag, wart",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg79L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 79,
    "text": "Seborrheic Kera\n\n Treatment may be indicate\n are inflamed, irritated or ble\n THERAPIES\n ◦ Cryotherapy; for flat to m\n ◦ Light cautery/electrodes\n ◦ Shave excision\n ◦ Laser\n Not effective for thick\n Ruby (694nm)\n Alexandrite (755nm)\n CO2\n Erbium",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg79R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 79,
    "text": "atosis - SK\n\ned for symptomatic lesions which\n eeding.\n\nminimally raised lesions.\n ssication\n\nker lesions",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg80L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 80,
    "text": "Actinic Keratosi\n\n Most common precancerous le\n prevalent in fair-skinned individ\n easily.\n\n Found in sun-exposed skin\n ◦ Face, ears\n ◦ Neck, forearms\n ◦ Dorsal hands\n Outdoor occupations, ionizing\n and arsenic exposure",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg80R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 80,
    "text": "is - AK\n\n esions in humans, and more\nduals who tan poorly and burn\n\n radiation,",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg81L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 81,
    "text": "Actinic Keratosi\n\n Common in skin type I-III\n\n Secondary to cumulative kera\n\n Atypical keratinocytes confin\n\n < 1% progress to skin cancer (",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg81R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 81,
    "text": "is - AK\n\natinocyte damage\n\ned to epidermal basal layer\n\n(squamous cell carcinoma, SCC)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg82L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 82,
    "text": "Actinic Keratosi\n\nClinical appearance\n\n - Slightly erythematous, rou\nareas\n\n - May be difficult to see, bu\nessential to diagnosis.\n\n - Most commonly in the eld\n\n - DDx: BCC, Bowen disease\n\n - Investigation: Biopsy if rec\nor pronounced hyperkeratos",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg82R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 82,
    "text": "is - AK\n\nugh, scaly papules on sun-exposed\n\n ut often feel rough: Palpation is\n\nderly\n\ne, SCC\n\ncurrent, unresponsive to treatment,\n is and induration",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg83L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 83,
    "text": "Actinic Keratosi\n\n Treatment options\n\n ◦ Topical\n 5% 5-flourouracil (Car\n wk\n 5% Imiquimod (Aldara\n weekly for 12 wk\n Expect erythema, irr\n follow-up visit in 1-2 wk\n effects",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg83R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 83,
    "text": "is - AK\n\nrac, Efudex) applied bid for 2-4\n\n ) applied three to five times\n\n itated, inflamed and crusting;\nk to evaluate severity of side",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg84L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 84,
    "text": "Actinic Keratosi\n\n ◦ Liquid Nitrogen Cryoth\n ◦ Electrodesication and\n ◦ Dermabrasion\n ◦ Chemical peel (for nu\n Serial medium dept\n ◦ Light Therapy\n PDT with ALA. Pulse\n\n Sun-awareness and pr",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg84R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 84,
    "text": "is - AK\n\nherapy for limited lesions\nd curettage, CO2 laser\n\n merous AKs)\n th TCA\n\n d CO2\n\n rotection advice",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg85L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 85,
    "text": "Basal Cell Carc\n\nMost common cutaneou\n cells of epidermis. Locally\n metastasizes (unless patie\n\nEtiology: Chronic UV exp\n is primary risk factor), rad\n genetics (e.g., nevoid ba\n\nHistory: Persistent, nonhea\n ulcerates or bleeds (beef\n Common in elderly (most",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg85R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 85,
    "text": "inoma - BCC\n\nus malignancy derived from stem\ny invasive, slow-growing, rarely\nents is immunocompromised)\n\n osure (Cumulative sun exposure\n iation, immunosuppression,\nasal cell carcinoma syndrome)\n\n aling papule or nodule that\n fy-red smooth erosive nodule).\n t common after 40) Caucasians.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg86L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 86,
    "text": "Basal Cell Carc\n\nPhysical: Pearly papule o\n rolled border; central cru\n\nDistributed mostly on sun\n neck (85%). Variants: Sup\n (morpheaform), pigment\n\nDDx: Melanoma, nevus, S\n\nInvestigations: Biopsy mu\n diagnosis and classify sub",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg86R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 86,
    "text": "inoma - BCC\n\nor nodule with telangiectases,\nust or ulceration.\n\n -exposed areas, i.e., head and\nperficial, nodular, sclerosing\n ted\n\nSCC\n\n st be performed to confirm\nbtype.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg87L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 87,
    "text": "Basal Cell Carc\n\nPhysical Findings\n\n- Nodular BCC: Most comm\nalmost translucent, dome-sh\ntelangiectasias. Papule or n\nbecome flattened in cente\ntranslucent border. Frequen\ncrusted in center",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg87R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 87,
    "text": "inoma - BCC\n\n on variant. A pearly white,\nhaped papule with overlying\nnodule enlarges slowly, may\n r or may develop a raised, rolled,\nntly ulcerates, bleeds, becomes",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg88L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 88,
    "text": "Basal Cell Carc\n\n- Pigmented BCC: contains\n resemble melanoma\n\n- Superficial BCC: least agg\n on trunk, extremities. Circu\n scaling plaque resembles\n extramammary Paget dise\n\n- Sclerosing BCC : Most sub\n Smooth, pale white to yel\n tissue. Borders may be diff\n recurrence",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg88R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 88,
    "text": "inoma - BCC\n\n s melanin, may therefore\n\ngressive form. More commonly\n umscribed, round to oval, red,\n eczema, psoriasis,\n ease or Bowen disease\n\nbtle and least common variant.\n low papules. Resembles scar\n ficult to discern. Higher rate of",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg93L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 93,
    "text": "Basal Cell Carc\n\nManagement\n\n - Advise that metastases and\nmajority cause no major prob\n\n - Without treatment, BCCs pe\ndestroy surrounding structure\n\n- Tx options depend on histo\n Liquid nitrogen cryotherap\n curettage & electrodessic\n Mohs micrographic surger\n subtype, 5-FU, CO2 laser, r\n\n- Advise on sun protection",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg93R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 93,
    "text": "inoma - BCC\n\nd death are extremely rare. Vast\nblem, but should be treated\n\n ersist, enlarge, ulcerate, invade,\n s\n\n ological subtype and location:\npy (requires experience),\ncation (most common Tx), excision,\n ry, imiquimod cream for superficial\n radiation therapy",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg94L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 94,
    "text": "Basal Cell Carc\n\nElectrosurgery of obvious\n approach 92%\n\nPrimary excision is preferr\n nodular. The 5 year rate a\n\nMohs microsurgery is a hi\n method of excision used\n contiguous growth. It is a\n histological aggressive fo\n BCCs, and tumors in ana\n such as around eyes, nas",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg94R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 94,
    "text": "inoma - BCC\n\n s tumor. The 5 year cure rate\n\n red for non-facial, well-defined\n approach 90%\n\n ighly specialized, tissue-sparing\n for difficult tumors with\nalso used for recurrent BCC,\n orms of BCC, such as sclerotic\n tomically important locations\n sal alar, mouth and ears.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg95L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 95,
    "text": "Basal Cell Carc\n\nRadiation therapy may b\n tumors, such as eyelids, a\n tolerate surgery. The 5 ye\n\nPhotodynamic therapy is\n modality for superficial BC\n\nTopical imiquimod 5% cre\n modifier shown to be abo\n superficial BCC. It is less e",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg95R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 95,
    "text": "inoma - BCC\n\nbe useful for difficult-to-treat\nand for patients unable to\near cure rates are roughly 90%\n\n s an evolving chemotherapeutic\nCC\n\neam is an immune response\n out 85% effective or better for\neffective for nodular BCC",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg96L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 96,
    "text": "Squamous Cell\n\n2nd most common form of skin\nexposed areas in elderly; due\nmetastatic potential.\n\nEtiology : Chronic UV-dama\n immunosuppression, burns\n (e.g., tar), HPV; can occur i\n & any scarring processes.\n\nHistory : Slow-growing, nonh\n exposed area of head, nec\n also affects mucous memb\n 10% - 15% metastatic rare);",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg96R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 96,
    "text": "Carcinoma (SCC)\n\n cancer (after BCC) arising in sun\n to malignant keratinocytes with\n\nage is the primary cause,\n leg ulcers, chemical carcinogens\n in discoid lupus, lichen sclerosus,\n\n healing scaly papule on sunck, dorsal hands, and forearms;\nbranes (lower lip: M >> F, smokers,\n rare in dark skin.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg97L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 97,
    "text": "Squamous Cell\n\nPhysical : Firm indurated p\n adherent rough scale on s\n necrotic crusted center. R\n cavity filled with necrotic k\n\nActinic keratosis is conside\n cheilitis is the precursor on\n\nUltimately, tumors metasta\n organs\n\nInvestigations : Biopsy (to m\n\nDDx : AK, BCC, SK, amelan",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg97R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 97,
    "text": "Carcinoma (SCC)\n\npapule, plaque, or nodule with\n sun-exposed areas. Normally with\nRemoval of crust reveals central\n keratin debris.\n\nered a precursor lesion; actinic\n lip.\n\n asize, via the lymphatics to other\n\n mid-dermis) for confirmation.\n\n notic melanoma, wart.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg99L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 99,
    "text": "Squamous Cell\n\nManagement\n\n Wide local excision with\n Lymp node biopsy indica\n Liquid nitrogen cryothera\n Mohs micrographic surge\n Less commonly topical im\n Advide on sun protectio",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg99R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 99,
    "text": "Carcinoma (SCC)\n\n histologic confirmation of margins.\nated for suspected nodal disease\napy\nery\nmiquimod or radiation\nn.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg100L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 100,
    "text": "Melanoma\n\nEtiology : Melanocyte-deriv\n a previously existing nevus o\n arise de novo\n\nHistory : Risk factors\n Fair complexion: Red/blond\n freckle and burn.\n Sun exposure, particularly b\n Personal of family history of\n cases: CDKN2A, BRAF.\n Giant congenital melanocy",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg100R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 100,
    "text": "ved skin cancer. May arise within\nor dysplastic nevus, but ~ 70%\n\nde hair, blue/green eyes, tendency to\n\nblistering sunburns during childhood.\n melanoma; Genes involved in some\n\n ytic nevi or multiple dysplastic nevi.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg101L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 101,
    "text": "Melanoma\n\nPhysical: Pigmented macule o\n following features\n\nABCDE of melanoma:\n\n- Asymmetry\n\n- Borders (irregular)\n\n- Color variegation\n\n- Diameter (> 6mm)\n\n- Evolution (lesion change by his",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg102L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 102,
    "text": "Melanoma\n\nClassically divided into subtypes based\n\n1. Superficial spreading malignant m\n\n2. Nodular melanoma.\n\n3. Acral-lentiginous melanoma – Mos\n Hispanics, mostly on volar skin of th\n\n4. Lentigo maligna melanoma – Dev\n face of elderly, slow-growing.\n\n5. Amelanotic melanoma – Pink-red.\n\n6. Rare variants.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg102R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 102,
    "text": "on clinical and histopathologic features:\n\nmelanoma – 60%-70% of melanomas.\n\n st common form in blacks, Asians, and\n he palms or soles and the nailbeds.\n\n velops from a lentigo maligna, usually on the\n\n .",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg108L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 108,
    "text": "Melanoma\n\nMost common sites of loca\n Draining lymph node basin\n primary site and the lymph\n\n- Most common sites of syste\n brain (#1 cause of death)\n\nInvestigations: Dermoscop\n melanomais suspected\n\nMost important prognostic\n tumor invasion on biopsy (\n\nDDx: BCC, blue or dysplas",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg108R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 108,
    "text": "al and/or regional metastasesns and the skin between the\nh nodes.\n\n emic metastases – Lung, Liver,\n , bone, and gastrointestinal tract.\n\npy (ABCD rule), excisional biopsy if\n\nc indicator is maximal thickness of\n(Breslow depth in mm)\n\n tic nevus, SK",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg109L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 109,
    "text": "Melanoma\n\nManagement\n\n- Wide surgical excision; bas\n melanoma in situ, 1 cm fo\n melanoma >1mm\n\n- Sentinel lymph node biops\n\n- Adjuvant high-dose interfe\n metastatic disease\n\n- Perfusion chemotherapy f\n\n- Radiation",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg109R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 109,
    "text": "sed on Breslow depth: 5 mm for\n r melanoma <1mm, 2 cm for\n\nsy depending on clinical\n\neron & IL-2 may provide benefit for\n\n or extremity melanoma",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg110L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 110,
    "text": "Atopic Dermati\n\nChronic inflammatory de\n children (esp. infants and\n\nEtiology: Cutaneous imm\n genetics. Strong associat\n history of atopy (eczema\n\nHistory: “Pruritus” is a hallm\n Aggravating factors: swe\n secondary infection, woo",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg110R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 110,
    "text": "tis\n\n ermatosis affecting 10%-20% of\n d young children)\n\nmune dysfunction; IgE-mediated;\n ted with personal and family\n a, asthma)\n\n mark (“the itch that rashes”).\n eating, contact sensitivity,\n ol, food allergy, stress/anxiety.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg111L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 111,
    "text": "Atopic Dermati\n\nAcute: Erythematous, excoria\n more lichenification in chroni\n\nDistribution:\n\n - Infants: Cheeks, forehead, sc\n\n - Child: Flexural surfaces- ante\nankles\n\n - Adults: Hands, flexural. The pr\nindicates a long – standing prob\n\nLesions can be secondarily in\n organisms: impetigo",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg111R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 111,
    "text": "tis\n\nated, scaling patches and plaques;\n c forms.\n\ncalp, extensor surfaces of extremities\n\n cubital and popliteal fossae, wrists,\n\n rominent finding is lichenification; this\n lem.\n\nnfected with staphylococcal",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg113L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 113,
    "text": "Atopic Dermati\n\nChild: Flexural surfaces- antecubit",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg114L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 114,
    "text": "Atopic Dermati\n\n Adults: Hands, flexural. The pro\n ; this indicates a long – standin",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg114R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 114,
    "text": "tis\n\nominent finding is lichenification\nng problem",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg115L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 115,
    "text": "Atopic Dermati\n\nDDx: Contact dermatitis,\n\nInvestigation: Allergy or R\n test if dermatitis pattern c\n treatment.\n\nDiagnosis Requires: Histor\n parental report of scratc",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg115R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 115,
    "text": "tis\n\n psoriasis, seborrheic dermatitis\n\nRAST testing of little value (Patch\nchanges or refractory to\n\n ry of an itchy skin condition (or\n hing/rubbing by the child)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg116L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 116,
    "text": "Atopic Dermati\n\n Plus ≥3 of :\n\n1. History of involvement of skin c\nankles or around the neck) or ch\n\n2. Personal history of asthma or h\nin 1st degree relative if < 4 years o\n\n3. History of generalized dry skin i\n\n4. Visible flexural dermatitis (or ec\nouter limbs in children < age 4 ye\n\n5. Onset under the age of 2 (do\nyears)",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg116R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 116,
    "text": "tis\n\ncrease (antecubital, popliteal, anterior\nheeks in children < 10 years\n\nhay fever (or history of atopic disease\n of age)\n\n in the past year.\n\nczema on the cheeks/forehead and\nears)\n\n not use as criterion if patient is < age 4",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg117L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 117,
    "text": "Atopic Dermati\n\nMinor, less specific featur\n\n- xerosis, ichthyosis, palmar h\nImmediate type 1 skin test re\nand feet, cheilitis, nipple ec\ncutaneous infection, perifol",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg117R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 117,
    "text": "tis\n\n re:\n\n hyperlinearity, keratosis pilaris.\n esponses, dermatitis of hands\nczema, increased susceptibility to\n licular accentuation",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg118L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 118,
    "text": "Atopic Dermati\n\nManagement\n\n - Elimination of precipitating\nfabrics; wear cotton clothes,\nrestriction if specific verified fo\n\n- Skin hydration: Baths with e\n nonfragranced emollient\n\n- Topical steroids: 1% hydroc\n and folds, midpotency ste\n ointments more occlusive",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg118R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 118,
    "text": "tis\n\n irritants: avoid wool and synthetic\n humidifier at home; dietary\n ood allergy; stress reduction.\n\n emollients, apply thick\n immediately after bath.\n\n cortisone ointment bid to face\neroids bid to other effected areas;\n and more effective than creams.",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg119L",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 119,
    "text": "Management\n\n - Steroid-sparing topical immu\nchildren > 2 yr: Pimecrolimus crea\nTacrolimus – moderate to severe\n\n - Oral antihistamines with seda\nrelief of the associated pruritus, e\ntid/qid)\n\n - If secondarily infected: antibio\n\n - If patients refractory to conve\nchoices include: PUVA or UVB lig\ncourses), methotrexate, cyclospo\ndermatologist",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  },
  {
    "id": "3-Lecture-Common-Skin-Disease-2019_pg119R",
    "doc_id": "3-Lecture-Common-Skin-Disease-2019",
    "page": 119,
    "text": "unomodulators can be used bid in\n am – mild to moderate eczema.\ne eczema.\n\n tive effect may offer symptomatic\n e.g., hydroxyzine (3-5 mg/kg/d divided\n\notic therapy\n\n ntional therapy, other systemic Tx\nght therapy, systemic steroids (short\n orine: usually administered by",
    "metadata": {
      "type": "medical_guideline",
      "source": "3-Lecture-Common-Skin-Disease-2019"
    }
  }
]